TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants With Clinical Chemistry Values of Potential Clinical Importance (PCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain score after cesarean section
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in percentage of excess weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in blood biochemical parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: False negative rate of sentinel node biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Numeric Rating Scale (NRS) for low back pain or radiating leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of clinical evaluation in rheumatoid arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure Rate
Endpoint domain: Mortality/survival
Primary endpoint: Changes in dietary intake (fruit and vegetables servings)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limitation of infarct size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional Recovery Assessed by 6 Minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mood Rating Scale Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: D1R to D2R striatal ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DA release
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day readmission prevalence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to Statins
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patency rate of internal iliac artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes in diaphragm's position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in diaphragm's shape and length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in diaphragm's efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in twitch transdiaphragmatic pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphocyte subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Reporting Prompted Local Reactions Within 7 Days After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Reporting Prompted Systemic Events Within 7 Days After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Reporting Serious Adverse Events (SAEs) up to 6 Months After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: infraauricular depressed deformities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gustatory flushing or sweating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grey Scale Ultrasound Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Glucose AUC at 12 Weeks From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hepatic Fat, Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adherence Rate to Diagnosis Imaging Guidelines for Deep Sarcoma Tumor
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence Rate to Diagnosis Imaging Guidelines for Superficial Sarcoma Tumor
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence Rate to Diagnosis Technique (Biopsy) Guidelines for Deep Tumors
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence Rate to Discussion in Multidisciplinary Team Meeting
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Exogenous glucose levels in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Non-ST segment elevation myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ST-segment elevation myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hunger and satiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Perceived Stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline in Psychological Well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in Cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Duration of Moderate Neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Detection of NSCLC on CT scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Clinical Global Impression - Improvement scale (CGI-I) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Amount of assistance needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood coagulation and hemostasis parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in pain score (NRS) in target knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence rate of any events
Endpoint domain: Mortality/survival
Primary endpoint: Quantity of patient controlled analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative morphine administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fentanyl requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Surgical success in POP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completing proportion
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of subjects with ovarian inhibition at treatment Cycle 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of subjects with ovarian inhibition at treatment Cycle 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Participants With Proximal Type I Endoleak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Fracture Healing Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in Hemoglobin A1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative duration of deviating vital signs: SpO2 < 85% min-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cumulative duration of deviating vital signs, respiratory rate ≤ 5 min-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cumulative duration of deviating vital signs, respiratory rate > 24 min-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cumulative duration of deviating vital signs, heart rate > 130 min-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative duration of deviating vital signs, heart rate ≤ 30 min-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cognition (working memory) accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognition (working memory) reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase 2 dose (RP2D)
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: In-segment Late Lumen Loss (LLL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Sensitivity of lung ultrasound and chest X-ray to detect community-acquired pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in Karnofsky performance status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Numbers of participants who experience adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Polyhydraminos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Participants With Fetal Growth Restriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Participants With Large for Gestational Age Fetuses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Participants With Oligohydraminos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Muscle evoked potential (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Movement error
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of spermatozoa with DNA damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Percent of Tumor-Infiltrating Lymphocytes (TIL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Braking performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Vital Signs Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood levels of anticancer drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduced pictorial blood assessment chart scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline in Plasma Lipids in Healthy Subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in Plasma Lipids in Subjects with Metabolic Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Caries lesion state of WSLs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dopamine Transporter Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cumulative obstetric and thrombotic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Area Over Baseline Over 12 Hours for the Incisal Bite Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in days of sick-leave
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in pain-related disability using Pain Disability Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in health related quality of life using EQ-5D
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in the rate of glucose disposal during insulin infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Cocaine Craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lower jaw size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower jaw projection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follicle stimulating hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction of lung atelectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Permanent chemotherapy-induced alopecia
Endpoint domain: Adverse events/effects
Primary endpoint: Uptake of influenza vaccination
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: C-SF-MPQ-2 score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: maximum tolerated dose (MTD) or optimal biological dose (OBD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Disease Score (DS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRSA Transmission Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Refusal to organ procurement
Endpoint domain: Adverse events/effects
Primary endpoint: reduction of number of exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: reduction of number of hospitalisations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence of Post-traumatic Carpal Tunnel Syndrome (CTS) or Complex Regional Pain Syndrome (CRPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in concentration of BLZ-100 in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: training scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants in each clinically defined group
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in Pain Perception Measured on Visual Analog Score (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving PASI score of ≥75
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence after primary tumor resection
Endpoint domain: Mortality/survival
Primary endpoint: Correct placement of NG tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Progression Free Survival (irPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Post Transplant Liver Function Test (PTLFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in UDysRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual shade matching performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total power (TP) spectrum of HRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High frequency (HF) spectrum of HRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low frequency (LF) spectrum of HRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non Administration of Prescribed VTE Prophylaxis Medication Doses
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentration of LX4211 and metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of clinical relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progression of disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year Event Free Survival (EFS)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Grade 3 Thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Grade 3 Neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Saliva concentration of naproxen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saliva concentration of naproxen-esomeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titers Against Homologous Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Objective response rate (RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 6-month Change in Ophthalmic Artery Peak Systolic Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 6-month Change in Central Retinal Artery Peak Systolic Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to viral suppression below 50c/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sensitivity and specificity of FDG-PET-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of distribution (VT) of cerebral KOR expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Mirikizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to t (AUC[0-tlast]) of Mirikizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardio-embolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in 24-hour Urinary Aldosterone Excretion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Plasma Aldosterone Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Finger tapping speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Stool Record (DSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of genetic abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breakthrough peripheral parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Laboratory toxicities classified as Grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Serious adverse events (SAEs) related to vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Toddlers' ability to learn sound patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of recovery (QoR)-15 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Health-Related Quality of Life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: changes in corneal parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects completing 12 cycles of maintenance therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative atrial fibrillation (AF) recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Procedural AF termination rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amount of physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety for the patient
Endpoint domain: Adverse events/effects
Primary endpoint: Stability of the graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: cGMP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent Signal Change in Ventral Tegmental Area (VTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Percent Signal Change in Right Ventral Striatum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Percent Signal Change in Right Medial Orbitofrontal Cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Percent Signal Change in Caudate Nucleus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Percent Signal Change in the Visual Cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With Negative Ice Cube Provocation Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise Capacity at Discharge 2 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise Capacity at Discharge 6 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise Capacity at Discharge 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct interpretation of pregnancy test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of patients that survive to Hospital Discharge
Endpoint domain: Mortality/survival
Primary endpoint: Cardiometabolic risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes